News

Treatment with plant-derived aloperine reduces the severity of lung injury in a mouse model of pulmonary fibrosis, a new Chinese study reports. The research, “Aloperine Protects Mice against Bleomycin-induced Pulmonary Fibrosis by Attenuating Fibroblast Proliferation and Differentiation,” was published in the journal Scientific Reports. Idiopathic PF…

The digital healthcare company patientMpower recently released a new platform called patientMpower for Lung Transplant for patients with pulmonary fibrosis (PF) and other conditions who have received a lung transplant. In January, patientMpower was one of three winners of the $1 million IPF Catalyst Challenge, an award given to projects focused on…

The rate of decline in lung function in patients with idiopathic pulmonary fibrosis (IPF) before they are treated with Genentech‘s Esbriet (pirfenidone) influences the effects of the medication, researchers have found. Patients classified as rapid progressors, who experience accelerated declines in lung function, benefited more from Esbriet…

AdAlta has changed the structure of its lead therapy candidate for AD-114, for the treatment of pulmonary fibrosis. The new product, renamed AD-214, has enhanced activity and improved stability compared to AD-114, allowing a better outcome, according to AdAlta. AD-214 retains key features of its precursor, as it…

Idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) may share a common disease mechanism — degradation of elastin in the lungs — suggesting its potential as a biomarker for both diseases, research shows. The study, “Increased circulating desmosine and age-dependent elastinolysis in idiopathic pulmonary fibrosis,”…

BerGenBio’s bemcentinib (BGB324) stops the progression of aggressive tissue scarring in the lungs and liver, preclinical-trial research shows. Researchers published the findings in the American Journal of Respiratory and Critical Care Medicine. The article is titled “Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis.” The results were also presented…

A gene called FOXF1 can inhibit the progression of idiopathic pulmonary fibrosis (IPF), according to scientists at the Cincinnati Children’s Hospital Medical Center. They reported that IPF patients’ lungs, as well as the lungs of mouse models of IPF, lack the gene in cells called myofibroblasts that play a…

A chemical found in certain types of vegetables displayed anti-tissue scarring activity in laboratory and mice lung-tissue experiments, a study reports. The results suggested that the chemical, sulforaphane, could be used to treat idiopathic pulmonary fibrosis, or IPF, researchers said. An article about the study, “Sulforaphane attenuates…

The U.S. Food and Drug Administration recently granted orphan drug status to Reviva Pharmaceuticals’ treatment candidate RP5063 for idiopathic pulmonary fibrosis (IPF). Reviva is now planning to launch Phase 2 studies testing RP5063 in both IPF and pulmonary arterial hypertension (PAH) patients. The FDA granted orphan…

A little-known government entity within the National Institutes of Health (NIH) is helping to lead U.S. efforts to speed up the development of therapies for some 7,000 rare diseases. The Office of Rare Diseases Research (ORDR), headquartered in Bethesda, Maryland, was established in 1993 within the NIH Office of the…